Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Differentiated Thyroid Cancer × donafenib × Endocrine × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2 Endocrine 2

Conditions

Differentiated Thyroid Cancer 2

Interventions

Thyrotropin Alfa 3 donafenib 2 Injections 2 surufatinib 1 pembrolizumab 1 lenvatinib 1 apatinib 1 anlotinib 1 Sorafenib 1 Iodine-131 1 Everolimus 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡